Absorption enhancers: Applications and advances

AAPS Journal

Volumn 14, Issue 1, 2012, Pages 10-18

  Aungst, Bruce J ^a  

^a QPS LLC   (United States)

Author keywords

absorption; bioavailability; enhancer; permeability

Indexed keywords

8 (N 2 HYDROXY 5 CHLORO BENZYL)AMINO CAPRYLIC ACID; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CAPSULIN; CHITOSAN; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; CYCLOPENTADECALACTONE; DESMOPRESSIN; DIGOXIN; ENOXAPARIN; EXCIPIENT; FONDAPARINUX; HEPARIN; HUMAN GROWTH HORMONE; INSULIN; ISIS 104838; LEUPRORELIN; MEDIUM CHAIN FATTY ACID; MORPHINE; OCTANOIC ACID; OCTREOTIDE; OSELTAMIVIR; POLYSORBATE 80; PROSTAGLANDIN E1; SODIUM N [8 (2 HYDROXYLBENZOYL)AMINO]CAPRYLATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR; VANCOMYCIN; ZANAMIVIR; ZOLEDRONIC ACID;

ACROMEGALY; CANCER CHEMOTHERAPY; CARCINOID; CELL MEMBRANE PERMEABILITY; COLITIS; DIABETES INSIPIDUS; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CONTROL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG PENETRATION; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIOSIS; ENTERIC COATED TABLET; EXCIPIENT COMPATIBILITY; FIRST PASS EFFECT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE ABSORPTION; LIVER METABOLISM; NOCTURNAL ENURESIS; NONHUMAN; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVERSE MICELLE; REVIEW; RISK BENEFIT ANALYSIS; SKIN PERMEABILITY; THROMBOSIS; TOXICITY TESTING;

ANIMALS; EXCIPIENTS; HUMANS; PEPTIDES; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PROTEINS; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 84857617880     PISSN: 15507416     EISSN: None     Source Type: Journal    
DOI: 10.1208/s12248-011-9307-4     Document Type: Review

References (40)

1. BJ Aungst 2000 Intestinal permeation enhancers J Pharm Sci 89 429 442 10737905 10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J 1:CAS:528:DC%2BD3cXis12ktbw%3D
2. ES Swenson WJ Curatolo 1992 Intestinal permeability enhancement for proteins, peptides and other polar drugs: mechanisms and potential toxicity Adv Drug Del Rev 8 39 92 10.1016/0169-409X(92)90015-I 1:CAS:528:DyaK38XptFWqsg%3D%3D
3. J Hochman P Artursson 1994 Mechanisms of absorption enhancement and tight junction regulation J Contr Rel 29 253 267 10.1016/0168-3659(94)90072-8 1:CAS:528:DyaK2cXjtlSrtr4%3D (Pubitemid 24156373)
4. JA Fix 1996 Strategies for delivery of peptides using absorption-enhancing agents J Pharm Sci 85 1282 1285 8961139 10.1021/js960158a 1:CAS:528:DyaK28Xms1CmtLw%3D (Pubitemid 27014180)
5. E Arbit M Kidron 2009 Oral insulin: The rationale for this approach and current developments J Diabet Sci Technol 3 562 567
6. DL Burcham BJ Aungst M Hussain MA Gorko CY Quon S-M Huang 1995 The effect of absorption enhancers on the oral absorption of the GPIIb/IIIa receptor antagonist, DMP 728, in rats and dogs Pharm Res 12 2065 2070 8786991 10.1023/A:1016289200422 1:CAS:528:DyaK28Xis12gsg%3D%3D (Pubitemid 26032300)
7. BJ Aungst H Saitoh DL Burcham S-M Huang SA Mousa MA Hussain 1996 Enhancement of the intestinal absorption of peptides and non-peptides J Cont Rel 41 19 31 10.1016/0168-3659(96)01353-3 1:CAS:528:DyaK28XltVOksLY%3D (Pubitemid 26246360)
8. H Zhang M Yao RA Morrison S Chong 2003 Commonly used surfactant, Tween 80, improves absorption of P-glycoprotein substrate, digoxin, in rats Arch Pharm Res 26 768 772 14560928 10.1007/BF02976689 1:CAS:528:DC%2BD3sXotFKktro%3D (Pubitemid 43073795)
9. A Guo P Hu PV Balimane FH Leibach PJ Sinko 1999 Interactions of a nonpeptidic drug, valacyclovir, with the human intestinal peptide transporter (hPEPT1) expressed in a mammalian cell line J Pharmacol Exp Ther 289 448 454 10087037 1:CAS:528:DyaK1MXit1Khtb0%3D (Pubitemid 29156062)
10. M Kondoh K Yagi 2007 Progress in absorption enhancers based on tight junction Expert Opin Drug Deliv 4 275 286 17489654 10.1517/17425247.4.3.275 1:CAS:528:DC%2BD2sXltVGrtrc%3D (Pubitemid 46772847)
11. PH Johnson D Frank HR Costantino 2008 Discovery of tight junction modulators: significance for drug development and delivery Drug Disc Today 13 261 267 10.1016/j.drudis.2007.10.023 1:CAS:528:DC%2BD1cXjsVSjtr4%3D
12. NN Salama ND Eddington A Fasano 2006 Tight junction modulation and its relationship to drug delivery Adv Drug Del Rev 58 15 28 10.1016/j.addr.2006.01. 003 1:CAS:528:DC%2BD28Xjs1WntLo%3D
13. 2+ dynamics in cytoprotective action by amino acids and cytotoxicity by sodium laurate, an absorption enhancer J Pharm Sci 95 2256 2265 16886194 10.1002/jps.20712 1:CAS:528: DC%2BD28XhtVChtbfF (Pubitemid 44568535)
14. JM Miller A Dahan D Gupta S Varghese GL Amidon 2010 Enabling the intestinal absorption of highly polar antiviral agents: ion-pair facilitated membrane permeation of zanamivir heptyl ester and guanidine oseltamivir Mol Pharm 7 1223 1234 20536260 10.1021/mp100050d 1:CAS:528:DC%2BC3cXosF2jtrY%3D
15. AC Williams BW Barry 1992 Skin absorption enhancers Crit Rev Ther Drug Carr Sys 9 305 353 1:CAS:528:DyaK3sXms1KnsQ%3D%3D
16. ML Francoeur GM Golden RO Potts 1990 Oleic acid: its effects on stratum corneum in relation to (trans)dermal drug delivery Pharm Res 7 621 627 2367329 10.1023/A:1015822312426 1:CAS:528:DyaK3cXks1Giu7w%3D (Pubitemid 20286529)
17. BJ Aungst JA Blake MA Hussain 1990 Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines Pharm Res 7 712 718 2395798 10.1023/A:1015859320604 1:CAS:528:DyaK3cXlsFymtLk%3D (Pubitemid 20278367)
18. JA Nicolazzo BL Reed BC Finnin 2005 Buccal penetration enhancers-How do they really work? J Contr Rel 105 1 15 10.1016/j.jconrel.2005.01.024 1:CAS:528:DC%2BD2MXlt1Smtb4%3D (Pubitemid 40805471)
19. AC Leary M Dowling K Cussen J O'Brein RM Stote 2008 Pharmacokinetics and pharmacodynamics of intranasal insulin spray (Nasulin) administered to healthy male volunteers: Influence of the nasal cycle J Diabet Sci Tech 2 1054 1060
20. X Ding P Rath R Angelo T Stringfellow E Flanders S Dinh, et al. 2004 Oral absorption enhancement of cromolyn through noncovalent complexation Pharm Res 21 2196 2206 15648250 10.1007/s11095-004-7671-9 1:CAS:528:DC%2BD2MXjslOqtQ%3D%3D (Pubitemid 40568433)
21. AWG Alani JR Robinson 2008 Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative Pharm Res 25 48 54 17846867 10.1007/s11095-007-9438-6 1:CAS:528:DC%2BD1cXkslSmtg%3D%3D
22. MGI Riley MC Castelli EA Paehler 2009 Subchronic oral toxicity of salcaprozate sodium (SNAC) in Sprague-Dawley and Wistar rats Int J Toxicol 28 278 293 19636071 10.1177/1091581809337737 1:CAS:528:DC%2BD1MXhtVGit77F
23. Karsdal MA, Byrjalsen I, Riis BJ, Christiansen C. Optimizing bioavailability of oral administration of small peptides through pharmacokinetic and pharmacodynamic parameters: The effect of water and timing of meal intake on oral delivery of salmon calcitonin. BMC Clin Pharmacol. 2008;8. doi: 10.1186/1472-6904-8-5.
24. MA Karsdal I Byrjalsen K Henriksen BJ Riis EM Lau M Arnold, et al. 2010 The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic parients: a 14 day randomized study Osteoarthr Cartil 18 150 159 19747581 10.1016/j.joca.2009.08.004 1:STN:280: DC%2BC3c%2FpvFOksg%3D%3D
25. S Maher TW Leonard J Jacobsen DJ Brayden 2009 Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic Adv Drug Del Rev 61 15 1427 1449 10.1016/j.addr.2009.09.006 1:CAS:528: DC%2BD1MXhsVWlsrrN
26. AA Raoof P Chiu Z Ramtoola IK Cumming C Teng SP Weinbach, et al. 2004 Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate J Pharm Sci 93 1431 1439 15124202 10.1002/jps.20051 1:CAS:528:DC%2BD2cXks12iu78%3D (Pubitemid 38725017)
27. LG Tillman RS Geary GE Hardee 2008 Oral delivery of antisense oligonucleotides in man J Pharm Sci 97 225 236 17721945 10.1002/jps.21084 1:CAS:528:DC%2BD1cXkslOqug%3D%3D
28. Salama P, Mamluk R, Marom K, Weinstein I, Tzabari M. Pharmaceutical compositions and related methods of delivery. US Patent Appl. 2010/0105627 A1.
29. R Eldor M Kidron E Arbit 2010 Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects Diabet Obes Metab 12 219 223 10.1111/j.1463-1326.2009.01153.x 1:CAS:528: DC%2BC3cXjvFCrtLo%3D
30. Kidron M. Methods and compositions for oral administration of proteins. US Patent Appl. 2011/0014247 A1.
31. SD Luzio G Dunseath A Lockett TP Broke-Smith RR New DR Owens 2010 The glucose lowering effect of an oral insulin (Capsulin) during an isoglycaemic clamp study in persons with type 2 diabetes Diabet Obes Metab 12 82 87 10.1111/j.1463-1326.2009.01146.x 1:CAS:528:DC%2BC3cXhvFajtbk%3D
32. G Bernstein 2008 Delivery of insulin to the buccal mucosa utilizing the RapidMist system Expert Opin Drug Deliv 5 1047 1055 18754753 10.1517/17425247.5.9.1047 1:CAS:528:DC%2BD1cXhtVGktrnJ
33. Modi P. Methods of administering and enhancing absorption of pharmaceutical agents. U.S. Patent No. 7,087,215 B2; 2008.
34. Crotts G, Ghebre-Sellassie I, Sheth A. Oral peptide pharmaceutical dosage form and method of production. US Patent 7,316,819; 2008.
35. JJ Arnold F Ahsan E Meezah DJ Pillion 2004 Correlation of tetradecylmaltoside induced increases in nasal peptide drug delivery with morphological changes in nasal epithelial cells J Pharm Sci 93 2205 2213 15295781 10.1002/jps.20123 1:CAS:528:DC%2BD2cXnsVegurw%3D (Pubitemid 39129618)
36. JJ Arnold MD Fyrberg E Meezan DJ Pillion 2010 Reestablishment of the nasal permeability barrier to several peptides following exposure to the absorption enhancer tetradecyl-β-D-maltoside J Pharm Sci 99 1912 1920 19894270 1:CAS:528:DC%2BC3cXht12gt78%3D
37. ET Maggio E Meezan DKS Ghambeer DJ Pillion 2010 Highly bioavailable nasal calcitonin-potential for expanded use in analgesia Drug Del Tech 10 58 63 1:CAS:528:DC%2BC3cXhtlCrur7N
38. M Thanou JC Verhoef P Marbach HE Junginger 2000 Intestinal absorption of octreotide: N-trimethyl chitosan chloride (TMC) ameliorates the permeability and absorption properties of the somatostatin analogue in vitro and in vivo J Pharm Sci 89 951 957 10861597 10.1002/1520-6017(200007)89:7<951::AID-JPS13>3.0. CO;2-1 1:CAS:528:DC%2BD3cXlt1ahurY%3D
39. A Vetter R Martien A Bernkop-Schnurch 2010 Thiolated polycarbophil as an adjuvant for permeation enhancement in nasal delivery of antisense oligonucleotides J Pharm Sci 99 1427 1439 19708062 10.1002/jps.21887 1:CAS:528:DC%2BC3cXmvVCltg%3D%3D
40. O Wong J Huntington T Nishihata JH Rytting 1989 New alkyl N, N-dialkyl-substituted amino acetates as transdermal penetration enhancers Pharm Res 6 286 295 2748516 10.1023/A:1015990222731 1:CAS:528:DyaL1MXktFansrg%3D (Pubitemid 19134605)